Valneva SE VLA

VALNEVA Declaration of shares and voting rights Status as of August 31, 2026__________________________________________________________________________________________ Company name: VALNEVARegistered office: Îlot Saint-Joseph Bureaux Convergence – Bât. A, 12 ter Quai Perrache – 69002 LyonRegulated market of Euronext Paris - Compartment B Declaration date: September 4, 2026 Number of shares composing the share capital of ValnevaTotal number of voting rights including suspended voting rights*Descri

In August 2026, Pfizer and BioNTech received U.S. FDA approval for their updated COMIRNATY COVID-19 vaccine targeting the XFG variant for high-risk individuals, while Pfizer and Valneva’s Lyme disease vaccine candidate PF-07307405 had its Marketing Authorization Application validated by the European Medicines Agency based on Phase 3 trial data. Together, these vaccine milestones highlight Pfizer’s ongoing role in infectious disease prevention across both seasonal COVID-19 protection and...

Restructuring efforts and Lyme vaccine regulatory timeline take center stage.

Pfizer (NYSE:PFE) and Valneva had their Marketing Authorization Application for a Lyme disease vaccine candidate validated by the European Medicines Agency, confirming it is ready for full review. The vaccine filing follows late stage clinical results that reported encouraging efficacy and safety in preventing Lyme disease. A recent patent report highlighted Pfizer as a leading holder of next generation antibody drug conjugate intellectual property in cancer treatment. For readers looking...

Pfizer stock has delivered a roughly 28% decline over the past five years, yet recent gains and a mixed set of valuation checks mean the current price is not an obvious bargain or clear bubble. With fresh product news and shifting expectations around its portfolio, investors are weighing whether the recent rebound leaves enough room for attractive long term returns. The share price is down about 28% over five years. This points to a company that has yet to fully reward long term holders...

Healthcare stocks were lower late Friday afternoon, with the NYSE Healthcare Index decreasing 0.4% a

Consumer spending fell in July while Middle East hostilities weigh on risk appetite, today, Aug. 14, 2026.

The European Medicines Agency validated the marketing authorization application for Valneva’s Lyme disease vaccine, which it developed with Pfizer

The FDA is “willing to review” an updated submission for Capricor’s Duchenne cell therapy, its CEO said. Elsewhere, a heart drug battle spilled into court and Rigel priced the first “Protac” medicine.

NEW YORK & LYON, France, August 14, 2026--Pfizer Inc. (NYSE: PFE) and Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announced that the European Medicines Agency (EMA) has validated the Marketing Authorization Application (MAA) for PF-07307405, the companies’ 6-valent outer surface protein A (OspA)-based Lyme disease vaccine candidate and will begin its assessment of the application.

Valneva SE (INRLF) navigates a transitional first half with a strong cash position and a clear focus on its pipeline, as it reaffirms full-year guidance despite a significant operating loss.

Valneva (NASDAQ:VALN) reported lower first-half revenue and wider losses for 2026, while maintaining its full-year sales outlook and emphasizing its cash position, restructuring measures and expectations for regulatory progress on its Lyme disease vaccine candidate with Pfizer. CEO Thomas Lingelbac

VALNEVA Declaration of shares and voting rights Status as of July 31, 2026__________________________________________________________________________________________ Company name: VALNEVARegistered office: Îlot Saint-Joseph Bureaux Convergence – Bât. A, 12 ter Quai Perrache – 69002 LyonRegulated market of Euronext Paris - Compartment B Declaration date: August 5, 2026 Number of shares composing the share capital of ValnevaTotal number of voting rights including suspended voting rights*Description

VALNEVA Declaration of shares and voting rights Status as of June 30, 2026__________________________________________________________________________________________ Company name: VALNEVARegistered office: Îlot Saint-Joseph Bureaux Convergence – Bât. A, 12 ter Quai Perrache – 69002 LyonRegulated market of Euronext Paris - Compartment B Declaration date: July 2nd, 2026 Number of shares composing the share capital of ValnevaTotal number of voting rights including suspended voting rights*Description

Dr. Gerd Zettlmeissl is appointed as Chair of the Board of Directors Lyon (France), June 25, 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that shareholders approved all resolutions recommended by the Board of Directors at the Company’s Annual General Meeting (AGM), held earlier today in Lyon, France. Key resolutions adopted included the approval of the 2025 financial statements, renewal of authorizations granted to the Board of Directors reg

Lyon (France), June 4, 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company (“the Company”), today announced the availability of documentation for its Annual General Meeting (“the Meeting”) to be held on June 25, 2026 at 2:00 p.m. CEST at the Sofitel Lyon Bellecour Hotel, 20 quai du Docteur Gailleton, 69002 Lyon (France). The Preliminary Notice of Meeting – including the agenda, the draft resolutions proposed by the Board of Directors, and instructions for participa